SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date
of Report (Date of the earliest event reported): June 22, 2006
NEUROCRINE BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
Delaware
(State or other
jurisdiction of
incorporation or
organization)
|
|
0-22705
(Commission File
Number)
|
|
33-0525145
(IRS Employer Identification
No.) |
| |
|
|
| 12790 El Camino Real
|
|
92130 |
| (Address of principal executive offices)
|
|
(Zip Code) |
Registrant’s telephone number, including area code: (858) 617-7600
N/A
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
| o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
| o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 |
| |
| o |
|
CFR 240.14d-2 (b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 |
| |
| o |
|
CFR 240.13e-4 (c)) |
TABLE OF CONTENTS
Item
1.02 Termination of a Material Definitive Agreement
Neurocrine
Biosciences, Inc. announced today that Neurocrine and Pfizer have
agreed to terminate the collaboration agreement to develop and
co-promote indiplon. As a result, Neurocrine will reacquire all
worldwide rights for indiplon capsules and tablets and will
independently develop indiplon for approval and commercialization. As
part of the termination provisions of the agreement, Pfizer will
continue to support indiplon for a period of up to 180 days to ensure
a smooth transition.
Item 9.01 Financial Statements and Exhibits
99.1 Press
Release dated June 22, 2006